Jimmy Jose ( Department of Clinical Pharmacy, Kasturba Medical College, Manipal University, Manipal, Karnataka, India )
Kavitha Saravu ( Department of Medicine, Kasturba Medical College, Manipal University, Manipal, Karnataka, India. )
Kanav Khera ( Department of Clinical Pharmacy, Kasturba Medical College, Manipal University, Manipal, Karnataka, India. )
Beena Jimmy ( Department of Clinical Pharmacy, Kasturba Medical College, Manipal University, Manipal, Karnataka, India. )
Barkur Anantha Krishna Shastry ( Department of Medicine, Kasturba Medical College, Manipal University, Manipal, Karnataka, India. )
April 2008, Volume 58, Issue 4
Case Reports
Abstract
Introduction
Case Report
Lansoprazole induced AIN was suspected and the drug was withdrawn on day 6. Renal biopsy report was supportive of AIN. A course of prednisolone (1 mg/kg) was started and the patients renal function tests showed a progressive improvement with SCr levels on day 19 and day 25 being 3.2 mg/dl and 2.0 mg/dl. Rechallenge with lansoprazole was not done. Subsequent follow ups showed a complete recovery, with SCr level 1.1 mg/dl and 0.9 mg/dl after a period of 8 and 15 months.
Discussion
Considering the 2 cases of lansoprazole induced AIN reported in literature1, the drug was withdrawn in both the cases and patient was treated with steroids. Subsequent follow up showed an improvement. Concomitant disease in one case included diabetes mellitus similar to our case. Our case has a similar presentation with regard to age of presentation, duration of treatment with PPI as in an analysis of series of PPI (omeprazole) induced AIN reported by Myers et al7 in which the average age at diagnosis was 65.8 years (range 36- 86) and average duration of PPI administration was 2.7 months (range 1 week to seven months).
The main direction of therapy is withdrawal of the offending drug and supportive management for acute renal impairment, with or without steroid treatment. Even though the evidence for use of steroids in drug induced AIN has come from small, uncontrolled studies and case reports, they may have a role and are frequently used. Available data demonstrates a higher number and a shorter time interval for recovery of renal function. Use of prednisolone has probably contributed to the early and complete recovery of renal function in our case.
With more wide spread use of PPIs including the relatively newer agents like lansoprazole, the potential for this rare but serious adverse reaction needs to be given due importance. Prompt evaluation of renal function is warranted in patients who develop non-specific symptoms while taking PPIs. Early recognition will assist in preventing irreversible renal injury.
References
2. Delve P, Lau M, Yun K, Walker R. Omeprazole- induced acute interstitial nephritis. NZ Med J 2003; 116: U332.
3. ADRAC. Interstitial nephritis with the proton pump inhibitors. Aust Adv Drug React Bull 2003; 22: 7.
4. Geevasinga N, Kairaitis L, Rangan GK, Coleman PL. Acute interstitial nephritis secondary to esomeprazole. Med J Aist 2005; 182: 235-6.
5. Moore I, Saye JA, Nayar A, Ahmed S, Tapson JS. Pantoprazole induced acute interstitial nephritis. J Nephrol 2004; 17: 580-1.
6. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239-45.
7. Myers RP, McLaughlin K, Hollomby DJ. Acute interstitial nephritis due to omeprazole. Am J Gastroenterol 2001; 96: 3428-31.
Journal of the Pakistan Medical Association has agreed to receive and publish manuscripts in accordance with the principles of the following committees:




